Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irbesartan/Amlodipine FDC in Essential Hypertension
NCT00950066Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jul 2009
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of irbesartan and amlodipine in essential hypertension (6 arms), sponsored by Sanofi. Primary endpoint: Change in Seated Diastolic Blood Pressure at 8 weeks. Started Jul 2009; status: completed.
02
Drugs
irbesartanamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00950066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00950066.